Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 29.50 GBp
Change Today +0.25 / 0.85%
Volume 10.0K
As of 11:35 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

scancell holdings plc (SCLP) Snapshot

Open
29.25 GBp
Previous Close
29.25 GBp
Day High
29.50 GBp
Day Low
29.25 GBp
52 Week High
06/1/15 - 44.75 GBp
52 Week Low
03/31/15 - 22.75 GBp
Market Cap
66.4M
Average Volume 10 Days
147.8K
EPS TTM
-0.01 GBp
Shares Outstanding
225.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SCANCELL HOLDINGS PLC (SCLP)

Related News

No related news articles were found.

scancell holdings plc (SCLP) Related Businessweek News

No Related Businessweek News Found

scancell holdings plc (SCLP) Details

Scancell Holdings PLC, a biopharmaceutical company, engages in the discovery and development of novel immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope technology platforms in the United Kingdom. It is involved in the development of SCIB1, a plasmid DNA vaccine, which is in I/II clinical trials for the treatment of melanoma; and SCIB2 that stimulates immune responses to the lung cancer antigen NY-ESO-1. The company has collaborations with Cancer Research Technology Limited; Immatics Biotechnologies GmbH; NIH; ImmunoVaccine Technologies; Ichor Medical Systems; and Merck KGaA. Scancell Holdings PLC was incorporated in 2008 and is based in Nottingham, the United Kingdom.

7 Employees
Last Reported Date: 09/3/14
Founded in 2008

scancell holdings plc (SCLP) Top Compensated Officers

Joint Chief Executive Officer, Chief Scientif...
Total Annual Compensation: 76.7K GBP
Joint Chief Executive Officer and Director
Total Annual Compensation: 70.0K GBP
Compensation as of Fiscal Year 2014.

scancell holdings plc (SCLP) Key Developments

Scancell Holdings PLC Announces Update on SCIB1 Phase 1/2 Clinical Trial in Stage III and IV Melanoma Patients

Scancell Holdings PLC presented updated and very encouraging data from the ongoing Phase 1/2 clinical trial of SCIB1, its DNA ImmunoBody being developed for the treatment of patients with melanoma, at the American Society of Clinical Oncology (ASCO) meeting in Chicago. The trial is an open label, non-randomized study to characterize the safety and tolerability of SCIB1 administered using Ichor's TriGrid delivery system, as well as provide initial assessment of the ability of SCIB1 to delay or prevent disease recurrence in patients with Stage III/IV melanoma. Among the sixteen Stage III (n=9) and Stage IV (n=7) subjects with melanoma that was resected at the time of study entry, the median of disease free and overall survival have not yet been reached. All sixteen subjects are still alive, and 11/16 have remained disease free with a median follow up duration of 34 months (range 27-46 months). In addition, the data showed that the procedure was well tolerated. The most common adverse events were injection site reactions, which were mild and transient. Overall, these results suggest that SCIB1, delivered by Ichor's TriGrid, is safe, tolerable, and may confer protection from recurrence of melanoma, with little associated toxicity. SCIB1, the first product candidate derived from Scancell's broad Immunobody platform to enter clinical testing, is a DNA vaccine which encodes a human antibody engineered to contain multiple T cell epitopes derived from melanoma antigens. Scancell's Immunobody technology is designed to facilitate recognition of these epitopes by the patient's immune system, resulting in activation of highly potent, tumor-specific T cells, translating into an effective anti-tumor response. Ichor's TriGrid platform, the first integrated and fully automated device for electroporation-mediated DNA administration in humans, is being used to deliver the SCIB1 DNA vaccine to overcome the suboptimal potency observed with DNA vaccines delivered by conventional injection. The TriGrid platform is being tested in clinical trials for a wide range of disease indications, and has been recently licensed by Janssen Pharmaceuticals Inc. and Pfizer for infectious disease and oncology indications, respectively.

Scancell Holdings plc Announces Latest Data from the Ongoing Phase 1/2 Clinical Trial of SCIB1

Scancell Holdings Plc announced that the latest data from the ongoing Phase 1/2 clinical trial of SCIB1, its DNA ImmunoBody being developed for the treatment of patients with melanoma, will be presented in a poster at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 29 - June 2, 2015. The summary of the results contained therein relates to data available at the time of abstract submission. A further update on clinical outcomes, including survival time, will be given as part of the poster presentation. SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. The trial is an open label, non-randomised study to determine the safety and tolerability of SCIB1 administered intramuscularly using an electroporation device (TDS-IM, manufactured by Ichor Medical Systems, USA). The study is also assessing immune response and anti-tumour activity, and the ability of SCIB1 to delay or prevent disease recurrence in patients with resected disease.

Scancell Holdings plc Announces SCIB2 Synergy with Checkpoint Inhibitor Blockade for Treatment of Lung, Oesophageal, Prostate and Other Epithelial Cancers

Scancell Holdings plc announced new data demonstrating that animals treated with a combination of SCIB2, the company’s ImmunoBody vaccine in development for the treatment of lung, oesophageal, prostate and other epithelial cancers, and checkpoint inhibition (blockade of the CTLA-4 immune checkpoint pathway), showed enhanced tumour destruction and significantly longer survival times than when either treatment was used alone. The data confirming the therapeutic effect of SCIB2 with this second checkpoint pathway follows previous announcement on 12 August 2014 of SCIB1's synergy with PD-1 blockade in animal models. In earlier pre-clinical studies, they have shown that administration of SCIB2 alone induced potent tumour-specific T cell responses associated with increased T cell infiltration into the tumour and enhanced proliferation of T cells within the tumour resulting in tumour rejection and long term survival. In the new study where higher doses of tumour cells were used, the combination of CTLA-4 blockade with SCIB2 vaccination resulted in a significant survival advantage over the individual treatments. Although patients with a relatively low tumour burden may benefit from SCIB2 alone, these results highlight the potential benefits of combining SCIB2 with CTLA-4 blockade, such as ipilimumab, for the treatment of patients with advanced disease. SCIB2 is a DNA plasmid targeting the cancer antigen NY-ESO-1. It induces high avidity CD8 and CD4 responses in pre-clinical models and unlike SCIB1 which is only suitable for patients with the HLA-A2 subtype (around 50% of patients), SCIB2 has been engineered to be effective in over 90% of immune subtypes, further enhancing the market potential and reducing the need for HLA screening prior to treatment. All future ImmunoBody vaccines will now be engineered to this new standard. Checkpoint inhibitors can enable the host immune system to recognise, attack and destroy cancer cells. However, checkpoint inhibitors will not work on their own if the patient fails to mount an adequate immune response to the tumour. Taking the brake off immunosuppressive T cells with either CTLA-4 or PD-1 blockade, whilst simultaneously pressing the accelerator with active immunotherapies such as SCIB1 or SCIB2, is increasingly regarded as offering potential for overwhelming the disease and increasing efficacy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCLP:LN 29.50 GBp +0.25

SCLP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SCLP.
View Industry Companies
 

Industry Analysis

SCLP

Industry Average

Valuation SCLP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 8.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SCANCELL HOLDINGS PLC, please visit www.scancell.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.